Byoung Chul Cho

TL;DR: The efficacy and safety of nivolumab in Korean patients with advanced or recurrent squamous or non-squamous NSCLC are consistent with previous reports.

TL;DR: In the Phase 1 portion of TRIDENT-1 study, repotrectinib demonstrated encouraging overall clinical activity in patients with ROS1 fusion+ NSCLC and TRK fusion+ solid tumors, especially in those pts with ROS said to be TKI naive.

TL;DR: RET gene alterations leading to constitutive kinase activity are identified as drivers of disease progression in multiple sclerosis patients and are associated with central giant cell granuloma in mice.

TL;DR: It is demonstrated that dovitinib induced cell-cycle arrest at G0–G1 phase and apoptosis by selective inhibition of RET kinase activity and ERK1/2 signaling in RET-rearranged LC-2/ad cells, suggesting thatDovit inib can be a potential therapeutic option for RET- rearranged LADC, in which acquired resistance to dov itin ib can be overcome by targeting Src.

TL;DR: In this paper, the authors evaluated long-term results of concurrent chemoradiotherapy (CRT) with 5-fluorouracil and cisplatin and the potential benefit of consolidation chemotherapy in patients with anal squamous cell carcinoma (ASCC).